Letters
Covid-19: What next for Valneva vaccine?
Valneva could appeal to the vaccine hesitant and may be more effective for longer
BMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o48 (Published 11 January 2022) Cite this as: BMJ 2022;376:o48
- Shyan Goh, orthopaedic surgeon
- Sydney, Australia
- sgoh{at}hotmail.com
The UK government’s treatment of the Valneva covid-19 vaccine is appalling.1
In September 2021, the health secretary, Sajid Javid, was quoted as saying of Valneva to the House of Commons: “It was also clear to us that the vaccine in question that the company was developing would not get approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) here in the UK.”2
Later, in Hansard, this was amended to “the vaccine in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.